Objectives: Early identification of patients who are at risk of prolonged status epilepticus (SE) and patients with high chances of full recovery despite prolonged SE may urge clinicians to intensify treatment rather than to withdraw care. We aimed to develop prediction models based on readily available clinical parameters to predict prolonged SE at seizure onset and to identify patients with high chances for full recovery. Methods: From 2005 to 2016, all adult SE patients treated at the University Hospital Basel, a Swiss medical care center, were included. Multivariable Poisson regression was performed to identify predictors of prolonged SE (defined as SE for >12, >24, and >48 hours) and return to baseline from prolonged SE. The area under the receiver-operating characteristic curves (AUROC) for prediction models was calculated. Results: Of 467 patients, the median age was 66.7 years and mortality was 12%.
| INTRODUCTION
Status epilepticus (SE) is a life-threatening neurologic emergency with high morbidity and mortality. [1] [2] [3] Among several factors, 1 SE duration has been identified as being linked to increased hospitalization days 4 and independently associated with high mortality. 3, 5, 6 A recent large population-based study from Germany revealed increasing short-term mortality from 9.6% in nonrefractory to 15 .0% in refractory and 39.9% in super-refractory SE, and that super-refractory SE represented 13% of all SE admissions, but resulted in 56% of all SE-related costs, 7 uncovering the clinical and economic impact of prolonged SE. On the other hand, patients surviving refractory and superrefractory SE can have relatively favorable outcomes compared to survivors of nonrefractory SE, with mostly substantial impairments in their quality of life. 8 Early identification of patients at risk of prolonged SE and timely recognition of patients with a high chance of full recovery despite having prolonged SE are keys to improved clinical outcome, as both insights may urge the clinician to intensify treatment rather than suggesting care withdrawal. Although studies have identified early predictors of the development of treatment refractory SE, 9 data regarding the prediction of SE duration and the chance of recovery from prolonged SE at seizure onset are lacking. Hence, clinicians are forced to base their recommendations to patients and relatives regarding the level of care on intuition and clinical judgement with the inherent risk of misjudgment and mistreatment. Many patients and their relatives would forgo further intensive treatment if survival were to come at the cost of substantial neurologic impairment. However, there are reports of survival from prolonged SE [10] [11] [12] [13] [14] [15] [16] [17] [18] and favorable outcome in this context. [19] [20] [21] Thus, reliable and timely identification of patients with potential good outcome despite having prolonged SE would be extremely helpful for patients, relatives, and treating physicians alike. We aimed to develop prediction models based on readily available clinical parameters to predict prolonged SE at seizure onset and to identify patients with high chances for full recovery.
| METHODS
This observational cohort study was performed at the University Hospital of Basel, a Swiss tertiary academic medical care center with up to 50 000 emergencies annually. The STROBE (Strengthening the Reporting of Observational Studies in Epidemiology) guidelines were followed to enhance the quality and standardization for the reporting of observational studies. 22 The study was approved by the local ethics committee (Ethikkommission Norwest-und Zentralschweiz) in compliance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments. Based on their review, patients' consent was waived.
| Data collection
From January 1, 2005, to December 31, 2016, clinical, laboratory and epileptologic data of all consecutive adult patients (ie, at least 18 years of age) with SE were included. Data were assessed with the digital institutional electroencephalography (EEG) and medical databases. Patients developing SE as a consequence of acute hypoxic-ischemic encephalopathy from cardiorespiratory arrest were excluded. Types, severity, treatment response, and duration (as defined below) of SE were assessed from the digital EEG database and defined as follows: SE types were defined in accordance with the current guidelines (ie, focal nonconvulsive SE without coma [with or without altered consciousness and absence SE], SE with motor symptoms [myoclonic and convulsive SE], and nonconvulsive SE with coma). 23 SE severity was quantified by the validated Status Epilepticus Severity Score (STESS) as described previously.
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The following clinical parameters were collected: gender, age, etiology (categorized as potential nonfatal and fatal etiologies as defined elsewhere 28 
| Antiseizure treatment
During the entire study, clinical procedures regarding diagnosis and treatment followed the current guidelines. 
| Outcomes
Prolonged SE duration, defined as SE for >12, >24, and 48 hours, and return to baseline were defined as primary outcomes. Return to baseline was defined as complete neurologic and functional recovery to the patients' premorbid status. Death at hospital discharge and death 30 days after SE onset were considered as secondary outcomes.
| Statistics
Patients were categorized into the following groups: (1) patients with SE up to 12 hours; (2) patients with SE of >12-24 hours; (3) patients with SE >24-48 hours; and (4) patients with SE >48 hours. Comparisons of these 4 groups were performed as follows. Analysis of variance (ANOVA) was performed for comparison of continuous variables and Pearson chi-square test with Fisher's exact test was appropriate for comparison of categorical variables. Parameters significantly differing in ANOVA among the 4 groups were included in a multivariable Poisson regression model to identify independent predictors of SE not terminating within 12, 24, or 48 hours. The area under the receiver-operating characteristic curves (AUROC) for the prediction model based on these predictors was calculated.
To further identify predictors of return to baseline in patients with SE for >48 hours, patients in SE >48 hours were categorized into patients with return and without return to baseline during their hospital stay. Univariable comparisons of proportions were performed by the chi-square test or the Fisher's exact test. For continuous variables, the Shapiro-Wilk test was used to distinguish between normally and not normally distributed variables. Normally distributed variables were analyzed with the Student's t test, whereas variables violating the normal distribution were analyzed with the Mann-Whitney U test. Variables significantly differing between patients in SE >48 hours with and without return to baseline were integrated in a multivariable Poisson regression model to identify independent predictors for return to baseline. The AUROC for the prediction model based on these predictors was calculated to evaluate discrimination. K-fold cross-validation was used to generate a more realistic estimate of predictive performance of the final prediction model. We evaluated the discrimination of the cross-validated model through calculation of the AUROC. To further challenge the predictive value of potential predictors for return to baseline in patients with prolonged SE, factors known to be associated with adverse outcome and occurring later in the course of SE were subsequently included in the final regression model (such as continuous administration of anesthetics and vasopressors 24, [35] [36] [37] [38] ).
To exclude the possibility of potentially biased associations between SE duration and unfavorable outcome (ie, no return to baseline or death) resulting from the reduction or withdrawal of care, sensitivity analyses were performed after excluding patients who died for both models.
Two-sided P values ≤0.05 were considered statistically significant. Statistical analysis was performed with STATA 14.2 (Stata Corp).
| RESULTS
Of 549 consecutive adult patients treated for SE, 82 patients with SE as a consequence of hypoxic-ischemic brain injury were excluded. Of the remaining 467 patients, the median age was 66.7 years, median SE duration 1 day (interquartile range 0.5-2), in-hospital mortality 11.8%, and mortality 30 days after SE onset 12.4%; 40.9% of patients F I G U R E 1 Distribution of patients with a specific duration of status epilepticus (upper part) and in-hospital outcomes among patient groups with a specific status epilepticus duration (lower part; n = 467) SUTTER ET AL.
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had return to baseline. The distribution of patients with a specific duration of SE is presented in Figure 1 (upper part). The longest SE was 43 days. Of the total cohort, 41.5% had confirmed potentially fatal etiologies, 49.5% had focal nonconvulsive SE without coma, 20.8% SE with motor symptoms, and 29.7% nonconvulsive SE with coma. The median STESS was 3 (interquartile range 2-4) and the median Charlson comorbidity index was 2 (interquartile range 1-4). Demographics, and further clinical and treatment characteristics, as well as detailed information regarding outcomes are compiled in the Table 1 . The relative risk (RR) for death was 1.06 (95% confidence interval [CI] 1.03-1.09; P < 0.0001) with every additional day in SE. Death and return to baseline significantly differed among the 4 patient groups with different SE duration, as shown in Figure 1 (lower part).
| Prediction of prolonged SE
Association between clinical and laboratory characteristics known at SE onset and duration of SE are presented in Table 2 . In univariable analyses, known epilepsy, nonconvulsive SE with coma, a STESS ≥3, acute brain lesions, and serum albumin levels at SE onset were significantly associated with increasing SE duration. Multivariable Poisson regression analyses for the prediction of SE not terminated within 12, 24, or 48 hours are presented in Table 3 . The independent predictors for ongoing SE within 24 and 48 hours were nonconvulsive SE with coma, acute brain lesions, and low albumin serum levels at SE onset. In patients with SE not terminated within 12 hours, nonconvulsive SE with coma and albumin serum levels were the only independent predictors. The Pearson and deviance goodness-of-fit tests revealed insignificant P values, indicating adequate model-fit. The AUROC was 0.68 for no SE termination within 12 hours, 0.67 for no SE termination within 24 hours, and 0.72 for no SE termination within 48 hours after SE onset.
| Prediction of return to baseline in prolonged SE (>48 hours)
One hundred two patients were in SE for >48 hours and were treated with a median of 4 antiseizure drugs (interquartile range 3-5) with continuous administration of benzodiazepines or anesthetics. There were no differences between patients with (25.5%) and without return to baseline (74.5%) regarding number of antiseizure drugs and anesthetics, and regarding complications during SE (including infections, organ failure, and severe arterial hypotension requiring the administration of vasopressors). Further univariable comparisons of clinical and laboratory parameters among patients in SE for >48 hours with and without return to baseline are presented in Table 4 , revealing that patients with return to baseline had a significantly lower proportion of nonconvulsive SE with coma, a less severe SE as quantified by the STESS, a lower Charlson comorbidity index, and lower C-reactive protein and higher albumin serum levels at SE onset. The multivariable Poisson regression model, however, identified absence of nonconvulsive SE with coma and a decreasing Charlson comorbidity index as the only independent predictors for return to baseline in these patients ( 
| DISCUSSION
Our study aimed to develop prediction models based on readily available clinical and laboratory parameters at seizure onset to predict whether patients will develop prolonged SE, and to identify patients with high chances of full recovery despite being in SE for >48 hours. Our study identified a significant increase in short-term mortality with increasing SE duration, a finding in line with those of prior studies. 3, 5, 6 A recent review of 37 studies regarding long-term outcome of patients surviving SE revealed that the long-term effect of SE duration on outcome is often difficult to distinguish from the underlying cause of SE. 39 In our cohort, the RR for death of 1.06 with every additional day in SE equals an increase in risk of death of 6% per 24 hours. This result, however, has to be interpreted with caution, as SE duration represents an approximation with an inaccuracy of a maximum of 12 hours. However, as patients with treatment refractory SE are always monitored with continuous video-EEG, a significant inaccuracy of SE duration in patients with prolonged SE (ie, SE of >12, >24, and >48 hours) seems very unlikely. The predictors for the development of prolonged SE in our study are similar to the predictors identified in an earlier 2-center study regarding the prediction of treatment refractory SE including a Swiss and American cohort. 9 In that study, acute etiologies, coma, and low serum albumin levels were independent predictors for refractory SE. Our attempt to generate a highly reliable prediction model for early recognition of patients at increased risk for developing prolonged SE failed, as demonstrated by the rather small AUROC and the fact that sensitivity analyses after exclusion of patients who died revealed inconsistent association of the identified predictors. Although the attempt to generate a reliable model for prediction of prolonged SE failed, the prediction model based on the independent predictors of return to baseline in patients with SE >48 hours showed a promising performance with an AUROC of 0.82 and consistency in sensitivity analyses of the identified predictors. Of interest, the only clinical variables at SE onset that were independent predictors of return to baseline following SE of >48 hours were the absence of nonconvulsive SE with coma and a low Charlson comorbidity index, whereas other factors, such as etiology, acute brain lesions, or factors emerging during SE (such as treatment aspects and complications) had no independent predictive value. These findings are mirrored by the results of an earlier case series of patients with prolonged SE which identified high morbidity and SE-associated coma to be associated with survival when 10 survivors of prolonged SE were compared with those of a matched cohort treated unsuccessfully for similarly prolonged episodes. 18 The strength of both identified predictors is further underscored by their remaining independence despite subsequent adjustments for well-known determinants of a complicated course of SE and adverse outcome (ie, intravenous anesthetics and vasopressors 24, [35] [36] [37] [38] ). These findings are of great clinical importance, as up to now, clinicians have had no reliable prediction tools to direct decisions regarding the level of care with progressive SE duration. Early and reliable identification of patients with potential favorable outcome despite having SE for several days is of outmost clinical importance, as this insight may urge clinicians to intensify treatment rather than consider care withdrawal as systemic and neurologic sequelae increase, and chances of SE termination decrease over time. Good outcome is possible after prolonged treatment refractory or super-refractory SE, with some patients returning to their premorbid status, even after >90 days of SE. 40 According to previous studies reporting outcomes after prolonged SE, younger age, absence of acute brain lesions at presentation, and the absence of multiple concomitant medical problems have been linked to favorable outcome. 20, 41 However, none of the studies performed multivariable regression models and generated or tested predictions models in this context. Although SE duration is associated with increased mortality in our cohort, our analyses indicate that it has no independent predictive value regarding outcome, and therefore should be interpreted with great caution. A decision to withdraw medical care should not be made based on SE duration. However, although internal cross-validation of the final prediction model indicated adequate performance, further external validation of our prediction model is warranted before our prediction model can be implemented and used for decision making in daily clinical practice.
| Limitations
The single-center observational design limits the generalizability of this study. However, the similarity of the clinical characteristics in our population to those in other SE studies including age, 44, 45 and types of SE, 42, 43, 46 indicates that our cohort has several characteristics typical of other large SE cohorts. Another limitation may be the approximation and therefore potential underestimation of SE duration, especially with unwitnessed onset, mainly the case with nonconvulsive SE. 2 However, given that patients with treatment refractory SE are always monitored with continuous video-EEG, an inaccuracy of SE duration in patients with prolonged SE (ie, SE of >12, >24, and >48 hours) seems highly unlikely. Continuous video-EEG had to be interrupted for several minutes to hours in almost all patients for several reasons including neuroimaging after continuous monitoring has been started, and intermittent interruption to avoid pressure ulcers of the scalp caused by the EEG electrodes, consequently more comprehensive and detailed analyses regarding the effects of SE duration and seizure density on outcome were not possible. However, these are unavoidable shortcomings that are likely to also affect the quality of prospective studies.
| CONCLUSIONS
Our study reveals that early identification of patients at high risk of prolonged SE based on clinical characteristics readily available at seizure onset is unreliable, calling for further research on this topic. Although it seems challenging to rapidly identify patients who will develop prolonged SE, our data indicate that timely recognition of patients in prolonged SE but with high chances of return to baseline despite having SE for several days is promising. However, further external validation of our prediction model is warranted before our model can be implemented in daily clinical practice.
